RecruitingNCT06870760

Pre-malignant States to Hematologic Malignancies in Firefighters


Sponsor

Wake Forest University Health Sciences

Enrollment

300 participants

Start Date

Jun 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.


Eligibility

Min Age: 40 YearsMax Age: 49 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether firefighters are at higher risk of developing early signs of blood cancers (such as leukemia or lymphoma) due to occupational exposure to hazardous substances encountered during firefighting. **You may be eligible if...** - You are between 40 and 49 years old - You are currently employed by the Charlotte Fire Department (CFD) - You have at least 5 years of on-the-job experience as a firefighter - You are able to understand and complete study procedures - You are willing to sign the informed consent form **You may NOT be eligible if...** - You have already been diagnosed with a blood cancer (such as leukemia, lymphoma, or myeloma) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMonoclonal Gammopathy

Whole blood will be collected at the Baseline visit to evaluate for monoclonal gammopathy through SPEP, immunofixation, and free light chains.

OTHERComplete Blood Count with differential (CBC w/ diff)

Whole blood will be collected at the Baseline visit for CBC with differential which may inform a diagnosis of a plasma cell disorder or other hematological disorder.

OTHERClonal hematopoiesis (CHIP)

Whole blood will be collected at the Baseline visit to be evaluated using next generation sequencing (NGS) detection of CHIP. Deep NGS to identify mutations associated with myeloid neoplasms and CHIP will be performed using an error-correcting next generation sequencing multi-gene panel targeting genes most frequently mutated in CHIP.


Locations(1)

Levine Cancer Institute

Charlotte, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06870760


Related Trials